Allergy Therapeutics (GB:AGY) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Allergy Therapeutics has revealed promising results from its Phase III trial for Grass MATA MPL, a short-course immunotherapy aimed at treating grass pollen allergies. The trial met its primary endpoint, showing a significant reduction in symptom and medication scores among participants, and the company is moving towards a marketing authorization application submission in Q4 2024. These results are expected to be detailed at a conference in June and could offer a new solution to those affected by seasonal allergies.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.